Foreign Drugs Welcome As China Reforms Progress: CFDA Commissioner
China’s drug regulators have had plenty of views to offer at recent major government congress sessions in Beijing, which provide a forum for the industry to meet officials and opportunities to outline reform progress and planned policies.
You may also be interested in...
Amid aftermath of latest vaccine scandal, top officials including China’s drug reform flagbearer are forced to resign, sending shock waves across the industry.
The China FDA releases a raft of new regulatory proposals outlining fundamental changes in areas including patent linkage and data exclusivity, which look set to profoundly impact decision makers looking at bringing new drugs and devices to the world’s second-largest pharma market.
The China FDA has outlined a raft of new measures to streamline the development and approval process for foreign new drugs, in changes that are likely to quicken the pace of launches to potentially overcome China’s “drug lag” and that may also bolster multinationals’ interest and activity in the country.